American College of Rheumatology

Ghaith Noaiseh, MD, explains how dazodalibep’s CD40 ligand blockade works and reviews dryness and safety data from OASIZ-301 at ACR 2026.

Ghaith Noaiseh, MD, discusses phase 3 OASIZ-301 results showing dazodalibep reduced systemic disease activity in Sjögren’s disease at ACR 2026.

John Stone, MD, MPH, discusses INDIGO open-label extension data showing durable flare control with obexelimab in IgG4-related disease at ACR 2026.

Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.

ACR 2026 real-world data associate upadacitinib with greater joint count reductions than IL-17 inhibitors after prior TNF inhibitor use.

ACR 2026 data link circulating protein signatures to PsA disease activity and treatment response with deucravacitinib.

Furie explains how nipocalimab clears IgG autoantibodies and why the JASMINE subgroups could shape phase 3.

The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.

An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.

In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.

RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.

In a matched claims analysis, 94% of patients with PMR initiating sarilumab discontinued glucocorticoids by 12 months vs 78% initiating methotrexate.

Patients with relapsing GCA who stopped upadacitinib after year 1 flared sooner and needed far more glucocorticoids than new-onset patients.

In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.

Philip Mease, MD, discusses BE BOLD head-to-head results plus new indirect and real-world comparisons shaping PsA treatment choices at ACR 2026.

Phase 3 data presented at ACR Convergence 2026 show up to 28.7% weight loss with the triple agonist, alongside sustained knee pain relief.

In phase 1 COMPARE, 4 of 6 patients with refractory RA achieved remission by week 36 following CD19 CAR T-cell therapy.

SABLE registry data show numerically lower 5-year mortality with belimumab vs conventional immunosuppressants in patients with SLE.

Once-weekly retatrutide reduced WOMAC pain and body weight vs placebo in two phase 3 trials, with up to 69.6% of participants halving knee pain at week 68.

Philip Mease, MD, discusses TOGETHER-PsA data on ixekizumab plus tirzepatide and why addressing obesity is becoming central to PsA care.

Two ACR Convergence 2026 studies tie GLP-1 receptor agonists to lower cardiovascular and mortality risk.

Philip Mease, MD, discusses pooled INSPIRE 1 and 2 data supporting tildrakizumab’s approval in psoriatic arthritis, presented at ACR 2026.

Two ACR 2026 abstracts report rising cardiovascular deaths in Sjögren syndrome and superior ESSDAI response with baricitinib vs hydroxychloroquine.

Kate Harnden, MBChB, PhD, discusses models predicting persistent arthritis after checkpoint inhibitor therapy, presented at EULAR 2026 and as an ACR plenary.

Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

ACR 2025 research shows polygenic risk scores correlate with specific SLE phenotypes, highlighting potential applications for clinical risk assessment.

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Mease discussed the latest updates on apremilast and growing attention to cardiometabolic outcomes at ACR Convergence 2025.